AstraZeneca 将来の成長
Future 基準チェック /46
AstraZeneca利益と収益がそれぞれ年間13.8%と6.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に28.4% 14.6%なると予測されています。
主要情報
13.8%
収益成長率
14.64%
EPS成長率
| Pharmaceuticals 収益成長 | 12.3% |
| 収益成長率 | 6.3% |
| 将来の株主資本利益率 | 28.40% |
| アナリストカバレッジ | Good |
| 最終更新日 | 08 Sep 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブ更新 • Sep 03
AZN: Oncology Wins And Trial Misses Will Shape Medium Term Path
AstraZeneca's analyst fair value estimate has been adjusted lower to £112.14 from £118.41, as analysts weigh a slightly higher discount rate against assumptions of steady long term revenue growth and margins, alongside mixed trial outcomes and ongoing confidence in the company's oncology pipeline and product catalysts. Analyst Commentary Recent research commentary on AstraZeneca presents a mixed picture, with supportive views on the oncology pipeline and long term revenue ambition set against a run of cautious updates on specific programs and overall execution risk.
ナラティブ更新 • Aug 13
AZN: Pipeline Strength And 2030 Revenue Ambition Will Drive Re Rating
Analysts have trimmed AstraZeneca's fair value estimate to £189.66 from £200.76, reflecting slightly higher assumed discount rates and more cautious long-term revenue growth expectations, partly informed by recent mixed trial outcomes and Street price target revisions. Analyst Commentary Recent Street commentary on AstraZeneca highlights a mix of caution around specific trial setbacks and corporate scenarios, along with continued confidence in the broader pipeline, execution, and long term growth ambition.
ナラティブ更新 • Jul 30
AZN: Oncology Approvals And Pipeline Progress Will Support Future Repricing
Analysts have trimmed their AstraZeneca price targets, with the modelled fair value easing from £164.85 to £159.11. This reflects slightly lower assumptions for revenue growth, profit margin and future P/E following recent trial setbacks and updated Street research.ナラティブ更新 • Jul 16
AZN: Trial Setbacks And Oncology Deals Will Shape Medium Term Credibility
AstraZeneca's updated analyst price targets show a modest reset lower, with recent research pointing to greater uncertainty around medium term revenue catalysts and mixed trial outcomes, even as some analysts continue to highlight areas of support within the broader pipeline and existing portfolio. Analyst Commentary Recent research on AstraZeneca highlights a mix of caution and support, with several firms revisiting their models after the CARDIO TTRansform outcome and reassessing how much risk investors are taking on around the medium term growth story.ナラティブ更新 • Jul 02
AZN: Oncology Approvals And Pipeline Execution Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets by about £10, citing updated assumptions that include a modestly lower fair value estimate, a slightly higher discount rate, and adjusted expectations for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on AstraZeneca points to a mix of product specific updates and valuation work, with several bullish analysts adjusting their views as new information filters through on the pipeline and regulatory outcomes.分析記事 • Jun 19
AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback
AstraZeneca (LSE:AZN) is back in focus after recent share price pressure, with the stock down about 5% over the past month and past 3 months. This has prompted investors to reassess its long term profile. See our latest analysis for AstraZeneca. Despite the recent share price decline, with the stock down 5.3% on a 90 day share price return basis and currently trading at £131.54, AstraZeneca still shows a 73.7% total shareholder return over five years. This suggests long term holders have seen...ナラティブ更新 • Jun 18
AZN: New Approvals And AI Use Will Support Future Repricing
The latest narrative update on AstraZeneca reflects a modest trimming of the analyst fair value estimate to £164.85, as analysts factor in updated revenue growth and profit margin assumptions following recent price target increases and ongoing commentary around the company’s drug pipeline and regulatory outcomes. Analyst Commentary Recent Street research around AstraZeneca centers on how regulators and pricing decisions may affect the company’s growth options, as well as how advisory outcomes could influence execution risk in parts of its pipeline.ナラティブ更新 • Jun 03
AZN: Recent Drug Approvals And Key Readouts Will Support Bullish Repricing
Analysts have lifted their AstraZeneca price targets by up to £1,000 per share, pointing to updated valuation work that reflects Baxfendy's FDA approval, recent price target revisions from several banks, and slight tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research around AstraZeneca clusters into two camps, with some analysts leaning more optimistic after Baxfendy's approval and a series of price target moves, while others highlight execution and regulatory questions that could affect how those targets are met.ナラティブ更新 • Apr 29
AZN: Pipeline Readouts And 2H26 Catalyst Path Will Drive Bullish Repricing
AstraZeneca's analyst price targets have been raised in recent research, with moves such as Guggenheim's lift to £160.00 and Citi's and Morgan Stanley's increases in their London based targets, as analysts point to refreshed models, updated earnings views and a more constructive stance on the pipeline. Analyst Commentary Recent research around AstraZeneca centres on refreshed valuation work, updated earnings paths and how the pipeline feeds into longer term growth expectations.ナラティブ更新 • Apr 15
AZN: Updated Oncology Pipeline Outlook Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets, with several recent moves in the £500 to £1,000 range. They cite stronger confidence in the earnings outlook and pipeline after updated models and conference follow ups.ナラティブ更新 • Apr 01
AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations
AstraZeneca's updated analyst price target reflects a modest uplift, with the fair value estimate moving from £117.29 to £124.85 as analysts factor in refreshed models after recent results, a higher assumed future P/E of about 25x, and ongoing optimism around the earnings pipeline highlighted in recent research. Analyst Commentary Recent research on AstraZeneca has included a series of price target revisions, with several large banks updating their models following full year results and subsequent investor events.ナラティブ更新 • Mar 18
AZN: Oncology Pipeline And Breast Cancer Trial Readouts Will Support Re Rating
Analysts have lifted AstraZeneca's fair value estimate from £182.81 to £205.97 and raised several price targets, citing updated models, a higher assumed profit margin and a more constructive view on the earnings pipeline. Analyst Commentary Recent Street research points to a cluster of upbeat views on AstraZeneca, with several bullish analysts revisiting their models and adjusting price targets after fresh company updates and sector readthroughs.ナラティブ更新 • Mar 03
AZN: Oncology Pipeline And 2H26 Catalysts Will Shape Balanced Long-Term Outlook
The updated analyst price target for AstraZeneca increases to £162.67 from £152.79. This reflects broader Street research that highlights stronger earnings potential and a more constructive view on the company’s pipeline and long term growth drivers.ナラティブ更新 • Feb 17
AZN: Elevated Margin Assumptions Will Face Pressure From Pipeline And Competition Risks
Narrative Update: AstraZeneca Analyst Price Target Shift Analysts have raised their fair value estimate for AstraZeneca from £108.53 to £117.29, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple, supported by recent price target increases and fresh bullish coverage across several banks. Analyst Commentary Recent Street research on AstraZeneca has leaned positive, with several banks adjusting fair value estimates and starting coverage with supportive views.業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 71,358 | 15,793 | 14,718 | 21,007 | 23 |
| 12/31/2027 | 66,913 | 13,768 | 13,054 | 18,923 | 27 |
| 12/31/2026 | 63,299 | 12,018 | 9,406 | 16,454 | 26 |
| 6/30/2026 | 61,366 | 10,446 | 6,250 | 13,700 | N/A |
| 3/31/2026 | 60,439 | 10,389 | 7,919 | 14,221 | N/A |
| 12/31/2025 | 58,739 | 10,225 | 8,806 | 14,575 | N/A |
| 9/30/2025 | 58,127 | 9,399 | 9,679 | 15,140 | N/A |
| 6/30/2025 | 56,501 | 8,295 | 8,327 | 13,389 | N/A |
| 3/31/2025 | 54,982 | 7,772 | 9,195 | 13,088 | N/A |
| 12/31/2024 | 54,073 | 7,035 | 7,398 | 11,861 | N/A |
| 9/30/2024 | 51,206 | 6,495 | 6,867 | 11,334 | N/A |
| 6/30/2024 | 49,133 | 6,440 | 7,045 | 11,065 | N/A |
| 3/31/2024 | 47,611 | 6,331 | 5,887 | 9,698 | N/A |
| 12/31/2023 | 45,811 | 5,955 | 6,858 | 10,345 | N/A |
| 9/30/2023 | 44,994 | 5,896 | 7,270 | 10,363 | N/A |
| 6/30/2023 | 44,485 | 6,163 | 6,854 | 10,179 | N/A |
| 3/31/2023 | 43,840 | 4,705 | 6,357 | 9,709 | N/A |
| 12/31/2022 | 44,351 | 3,288 | 7,684 | 9,808 | N/A |
| 9/30/2022 | 45,155 | 2,040 | 6,538 | 8,828 | N/A |
| 6/30/2022 | 44,038 | -1,253 | 5,789 | 7,617 | N/A |
| 3/31/2022 | 41,487 | -1,063 | 5,721 | 7,261 | N/A |
| 12/31/2021 | 37,417 | 112 | 4,350 | 5,963 | N/A |
| 9/30/2021 | 32,816 | 1,471 | 5,184 | 6,343 | N/A |
| 6/30/2021 | 29,528 | 3,771 | 5,421 | 6,446 | N/A |
| 3/31/2021 | 27,583 | 3,977 | 4,899 | 6,594 | N/A |
| 12/31/2020 | 26,617 | 3,196 | 3,144 | 4,799 | N/A |
| 9/30/2020 | 25,871 | 2,497 | 3,273 | 4,376 | N/A |
| 6/30/2020 | 25,699 | 2,148 | 3,057 | 3,657 | N/A |
| 3/31/2020 | 25,247 | 1,522 | N/A | 3,495 | N/A |
| 12/31/2019 | 24,384 | 1,335 | N/A | 2,969 | N/A |
| 9/30/2019 | 24,137 | 2,056 | N/A | 3,818 | N/A |
| 6/30/2019 | 23,071 | 2,188 | N/A | 3,184 | N/A |
| 3/31/2019 | 22,403 | 2,408 | N/A | 2,371 | N/A |
| 12/31/2018 | 22,090 | 2,155 | N/A | 2,618 | N/A |
| 9/30/2018 | 21,450 | 2,422 | N/A | 1,391 | N/A |
| 6/30/2018 | 22,342 | 2,677 | N/A | 3,165 | N/A |
| 3/31/2018 | 22,238 | 2,804 | N/A | 3,350 | N/A |
| 12/31/2017 | 22,465 | 3,001 | N/A | 3,578 | N/A |
| 9/30/2017 | 22,273 | 3,542 | N/A | 4,541 | N/A |
| 6/30/2017 | 21,740 | 3,870 | N/A | 3,109 | N/A |
| 3/31/2017 | 22,292 | 3,390 | N/A | 3,040 | N/A |
| 12/31/2016 | 23,002 | 3,499 | N/A | 4,145 | N/A |
| 9/30/2016 | 23,816 | 2,465 | N/A | 2,756 | N/A |
| 6/30/2016 | 24,062 | 2,221 | N/A | 3,690 | N/A |
| 3/31/2016 | 24,766 | 2,921 | N/A | 4,589 | N/A |
| 12/31/2015 | 24,708 | 2,825 | N/A | 3,324 | N/A |
| 9/30/2015 | 25,025 | 1,696 | N/A | 4,595 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: AZNの予測収益成長率 (年間13.8% ) は 貯蓄率 ( 3.6% ) を上回っています。
収益対市場: AZNの収益 ( 13.8% ) はUK市場 ( 11.4% ) よりも速いペースで成長すると予測されています。
高成長収益: AZNの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: AZNの収益 ( 6.3% ) UK市場 ( 3.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: AZNの収益 ( 6.3% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: AZNの 自己資本利益率 は、3年後には高くなると予測されています ( 28.4 %)
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/09 10:50 |
| 終値 | 2026/09/09 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
AstraZeneca PLC 27 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。57
| アナリスト | 機関 |
|---|---|
| null null | ABG Sundal Collier |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |